MDA-19
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
1048973-47-2  |
| PubChem (CID) | 25034599 |
| ChemSpider |
24689676 |
| Chemical and physical data | |
| Formula | C21H23N3O2 |
| Molar mass | 349.426 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
 (what is this?) (verify) | |
MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects.[1][2]
See also
References
- ↑ Diaz, Philippe; Xu, Jijun (2008). "Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain". J. Med. Chem. American Chemical Society. 51 (16): 4932–4947. doi:10.1021/jm8002203. PMID 18666769.
- ↑ Xu, JJ; et al. (Jul 2010). "Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain". Anesthesia and Analgesia. 111 (1): 99–109. doi:10.1213/ANE.0b013e3181e0cdaf. PMC 3253719
. PMID 20522703.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.